• <tbody id="ecjde"></tbody>

              20200716110716_41794.jpg

              Changchun BCHT Biotechnology Co. (hereinafter referred to as “BCHT” or “the company”) is an innovative biopharmaceutical enterprise committed to the prevention and control of infectious diseases. Since its establishment in 2004, BCHT has been engaged in research and development, manufacturing and distribution of vaccines for human use. Through years of development, BCHT has gradually established a complete operation system around core products and implemented quality management in the whole life cycle of products, including raw material procurement, project R&D, production management, product circulation, quality control and quality assurance. All links have strict management measures and internal control systems. BCHT now owns three manufacturing sites which cover 225,700 square meters in total. Relying on its core technology R & D and industrialization capabilities, BCHT has formed a stable business model, high market recognition and respectable social image.

              In June 2021, the company made its initial public offering and was successfully listed on the Science and Technology Innovation Board (STAR Market), with a total share capital of 412,860,698 shares and an issue price of 36.35 yuan per share. The number of shares issued accounted for 10% of the total share capital after this issuance, and the total amount of funds raised was about 1.5 billion yuan.

              BCHT has been awarded as High-tech Enterprise by Jilin Provincial Science and Technology Agency and other departments, as well as Research Center for Modern Vaccines, Jilin Vaccine Science and Technology Innovation Center, Vaccines Engineering Research Center at Changchun National Bio-Industry Base, and assigned as Jilin Science and Technology Small Giant Enterprise, Province AAA Creditrating Enterprise, Provincial Quality Creditable Enterprise, Changchun Science and Technology Small Giant Enterprise, Changchun Top 100 Small and Medium-sized Enterprises, Changchun Intellectual Property Demonstration Enterprise and Changchun Top 100 Private Enterprises. In 2018, BCHT won the 3.15 Top Ten Influential Brands of Chinese Medicine.

              The company takes product quality as its foundation, takes product innovation and R&D as the source of development, rationally sets up and optimizes the organizational structure to cooperate with development strategies, and lays out R&D pipelines for comprehensive development. The company’s independent intellectual property product, Varicella Vaccine, Live was successfully marketed in 2008. With four times upgraded, it is the first domestic varicella vaccine to remove animal-derived gelatin from adjuvant, which greatly reduces the incidence of adverse reactions. It is the first varicella vaccine with a validity period of 36 months in the world and its stability is the best among similar products. The market share has been the first in China for many years. 

              Our new vaccine — Influenza Vaccine, Live, Nasal, Freeze-dried (launched in 2020) is a cooperative project with World Health Organization, which has been included in WHO Global Action Plan for Influenza Vaccines and is the exclusive LAIV in China. This vaccine can be mass produced in a short time, which is conducive to expanding market share. Its nasal spray administration is easy to use, good compliance and willingness will benefit in mass immunization, which is very important for influenza prevention and control in China. The vaccine fills the market gap of domestic LAIV, has broad market prospects, and will be a new economic growth point of BCHT.

              BCHT has continued to invest heavily in R&D and create the Herpes Zoster Vaccine, Live for people aged at or above 40 years old. The vaccine has been proven to be safe and effective through a large-scale Phase III clinical trial and was approved for marketing in January 2023. The Herpes Zoster Vaccine, Live produced by BCHT not only achieves a breakthrough in population expansion, but also fills the gap in domestic herpes zoster vaccines market, providing a new preventive measure for more eligibles.

              BCHT has 1,241 employees, 725 with bachelor degree or above and 134 R&D staff. The company attaches great importance to the introduction and cultivation of high-end talents. At present, bachelor degree or above accounts for more than 55% of the total number of employees, with one expert enjoying special allowances from the State Council, one national "New Century Talent Project", 3 top innovative talents (level I) in Jilin Province and many overseas returnees.

              Led by several core technicians, BCHT has established a professional, stable and experienced R & D team. Since its establishment, it has been committed to the R&D and industrialization of biological vaccines and biological drugs. At present, there are three approved vaccine products: Varicella Vaccine, Live, Influenza Vaccine, Live, Nasal, Freeze-dried and Herpes Zoster Vaccine, Live. Meanwhile, BCHT has 13 vaccines under research and 3 full human monoclonal antibodies for infectious disease prevention and control, of which adsorbed acellular DPT (three component) combined vaccine and live attenuated influenza vaccine (liquid) are under clinical studies, full human monoclonal antibody against rabies has got the approval notification of clinical trial.

              亚洲精品视频一二三四区_熟妇人妻中文字幕_国产高清作爱视频_2021国产黄色综合